Product Images Tizanidine Hydrochloride

Each capsule of the medication contains 2.2 mg of tizanidine hydrochloride, which is equal to 2 mg of tizanidine base. The medication should be stored at 25°C (77°F) and can be kept between 15° to 30°C (50° to 86°F). The usual dosage should be referred to the package insert for prescribing information. The medication should be dispensed in containers with child-resistant closures and kept out of the reach of children. Zanaflex®, the medication is a registered trademark of Acorda Therapeutics Inc. There are 150 capsules in each container. The medicine is manufactured by Cadila Pharmaceuticals Limited in Gujarat, India.*

Each capsule of this medication contains 4 mg tizanidine base, equivalent to 4.58 mg tizanidine hydrochloride. It is recommended to store the capsules between 15°C to 30°C (50°F to 86°F) with excursions permitted. The package insert contains the usual dosage and prescribing information, and it must be dispensed in containers with a child-resistant closure. The medication should be kept out of children's reach, and Zanaflex is a registered trademark of Acorda Therapeutics Inc. The manufacturer of this medication is Caila Pharmaceuticals Limited in Gujarat, India.*

This text presents the results of a study comparing the effectiveness of tizanidine and a placebo in reducing the Ashworth score in individuals. The study tracked the progress of participants up to Week 7, using a mean dose of 28.8 mg of tizanidine. The "End of Titration" point was at Week 3 and the "End of Maintenance Endpoint" was at Week 7. The results suggest that tizanidine may lead to an improvement in Ashworth score compared to a placebo.*